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Abstract
Rett syndrome (RTT) is a severe genetic disorder resulting from mutations in the X-linked MECP2 gene. MeCP2 protein is
highly expressed in the nervous system and deficiency in the mouse central nervous system alone recapitulates many
features of the disorder. This suggests that RTT is primarily a neurological disorder, although the protein is reportedly widely
expressed throughout the body. To determine whether aspects of the RTT phenotype that originate in non-neuronal tissues
might have been overlooked, we generated mice in which Mecp2 remains at near normal levels in the nervous system, but is
severely depleted elsewhere. Comparison of these mice with wild type and globally MeCP2-deficient mice showed that the
majority of RTT-associated behavioural, sensorimotor, gait and autonomic (respiratory and cardiac) phenotypes are absent.
Specific peripheral phenotypes were observed, however, most notably hypo-activity, exercise fatigue and bone abnormalities.
Our results confirm that the brain should be the primary target for potential RTT therapies, but also strongly suggest that
some less extreme but clinically significant aspects of the disorder arise independently of defects in the nervous system.
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Introduction
Rett Syndrome (RTT) is an X-linked genetic disorder that is a
leading cause of intellectual disability in girls and women (1).
Diagnostic features of typical RTT include a highly character-
istic developmental regression involving loss or impairment
of mobility and loss of learnt speech and skilled intentional
hand movements, accompanied by stereotypic hand move-
ment automatisms. Associated features, such as microceph-
aly, respiratory/autonomic abnormalities, seizures, growth
deficits and early hypotonia are highly prevalent (1,2). Later in
childhood, RTT patients often develop prominent skeletal
signs including severe scoliosis, early osteoporosis and a pro-
pensity to suffer low-impact fractures and hip deformities
(3–5). In the vast majority of cases RTT is caused by de novo
mutations in the MECP2 gene, which encodes methyl-CpG
binding protein 2 (MeCP2) (6), an abundant nuclear protein
that is considered to be important in chromatin-level regula-
tion of transcription (7). MeCP2 is thought to mediate
transcriptional inhibition by binding to methylated CpG and
CpA dinucleotides in the genome (8–10) and recruiting co-
repressor complexes (11–14). Other reports suggest MeCP2
may also function as an activator of transcription (15)
amongst other functions (7).
Mouse models of RTT have been developed that typically
recapitulate many of the characteristic features of the human
disorder and allow the underlying pathogenic mechanisms
involved to be investigated (16,17). Two studies reported
that deletion of Mecp2 specifically in the nervous system re-
sults in the full range of RTT-like phenotypes (16,17), suggest-
ing that the disorder is primarily neuronal in origin. These
studies only investigated gross aspects of the phenotype,
however, such as body weight, survival and brain size. It is
possible that the shortened lifespan of null model masks phe-
notypes that are either subtle or delayed in their onset. In ad-
dition, more recent studies have identified a number of novel
phenotypes, including cardiovascular abnormalities (18,19),
lung abnormalities (20), bone and skeletal muscle defects
(21–23) and altered cholesterol biosynthesis (24–26). MeCP2-
deficiency outside the nervous system (that is, in the “periph-
ery”) potentially contributes to these phenotypes. MeCP2 is
widely expressed, with high levels reported in specific cell
types of heart, lung and various other peripheral tissues
(27–28). These findings highlight our ignorance of the relative
contributions of MeCP2-insufficiency in the nervous system
versus peripheral tissues to the pathogenesis of MeCP2
disorders.
To address this knowledge gap, we generated a mouse
model in which Mecp2 is silenced in peripheral tissues, but
reactivated prenatally at near normal levels within the nervous
system. Using this model, we investigated the peripheral contri-
bution to the major RTT-like phenotypes, as well as less promi-
nent aspects of the disorder. We also carried out in-depth
analysis of aspects of tissue function using metabolic and other
tests to seek previously undetected phenotypes. The experi-
ments reveal that the major features that characterise RTT re-
sult from lack of MeCP2 in the nervous system. Lack of MeCP2 in
the periphery, however, resulted in phenotypes that match spe-
cific clinical features associated with RTT, including reduced
stamina and bone abnormalities. Thus, while the nervous sys-
tem should be the major focus for targeting future RTT thera-
pies, our results suggest that a subset of phenotypes may be
peripheral in origin and may therefore benefit from systemic
level interventions.
Results
Levels of native MeCP2 in the nervous system and
peripheral tissues
We first measured levels of MeCP2 expression in several
mouse tissues in comparison with brain, using quantitative
western blotting of whole tissue homogenates. As an internal
calibration control, we chose histone H3, as this protein is a
component of the nucleosome core that is present in a con-
stant ratio with DNA and therefore cell number in somatic tis-
sues. The results of biological triplicate experiments gave
consistent results showing that levels in a variety of peripheral
tissues are approximately an order of magnitude lower per av-
erage cell than in the nervous system (Fig. 1A). Levels in the
forebrain, mid- and hind-brain and spinal cord are above the
average level for whole brain, but cerebellum is significantly
lower than other tested brain regions. It is likely that average
MeCP2 abundance in the brain is reduced by the contribution
of cerebellar granule cells, which are the most abundant and
among the smallest neurons in the brain. Our findings are at
variance with a previous estimate of MeCP2 abundance in
mouse tissues, which concluded that MeCP2 is most highly ex-
pressed in lung and somewhat lower in spleen and brain (29).
In that study protein levels were normalised to glyceraldehyde
3-phosphate dehydrogenase (GAPDH) and alpha-tubulin, both
of which are cytoplasmic proteins whose abundance in cells of
different sizes is unlikely to be constant. Histone H3 has
greater validity as a comparator, as nucleosomes uniformly
coat the genome with a periodicity close to 200 base pairs in
multiple cell types and organisms. Consistent with this gener-
alisation, the histone:DNA ratio has long been known to be
close to 1:1 for chromatin from diverse sources (30,31). These
observations, together with previous evidence that MeCP2 is
extremely highly expressed in neurons (32), argue that the pre-
sent findings accurately reflect low levels of MeCP2 protein in
tissues outside the nervous system.
Generation ofMecp2 peripheral knockout mice
To generate mice in which MeCP2 is selectively present in the
nervous system, but largely absent in the periphery, we utilised
a mouse line in which Mecp2 has been silenced by a stop cas-
sette targeted to the Mecp2 locus (33). It was shown previously
that the stop cassette causes a>95% reduction in MeCP2 levels
and is functionally almost equivalent to a full knockout allele
(34). The stop cassette in this line, referred to as KO, is flanked
by loxP sites whose deletion by cre results in efficient restora-
tion of normal expression and reverses phenotypic defects
(33,34). To generate a ‘peripheral knockout’ (PKO; Fig. 1B), we
reactivated the Mecp2 gene specifically in neurons and glia of
the nervous system (Fig. 1B) by crossing with a mouse line ex-
pressing cre from the nestin promoter (35). Southern blot analy-
sis revealed a high recombination frequency in the brain of PKO
mice (90%), but very low levels of recombination (below 15%)
in all other tissues tested (Fig. 1C and D) with the exception of
kidney (24%). These values agree with the previously re-
ported expression patterns of nestin-cre (35,36). This was con-
firmed at the protein level by quantitative western blots (Fig. 1E
and F) and anti-MeCP2 immunolabelling of tissue sections
(Supplementary Material, Fig. S1), which showed near wildtype
levels of MeCP2 in the brain and spinal cord, but greatly reduced
levels in other tissues. We conclude that the PKO mouse retains
MeCP2 expression in the vast majority of cells in the nervous
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Figure 1. Generation of a CNS rescue or ‘peripheral knockout’ mouse. (A) Plot showing levels of native MeCP2 protein relative to whole brain levels (and standar-
dised to histone H3 levels) in wild type (WT) mice as revealed by quantitative immunoblot (mean6 S.D., n¼3). (B) Cartoon showing MeCP2 expression profile in
three experimental cohorts of mice including WT, knockout (KO) in which Mecp2 is silenced globally using a stop cassette, and a peripheral knockout (PKO) mouse
in which Mecp2 is silenced in the peripheral tissues but reactivated in the nervous system using nestin-cre mediated recombination of an Mecp2-stop allele. (C)
Representative Southern blots showing recombination of the Stop/y allele (5.1 kb) to delete the Stop cassette (open triangle, 4.3 kb) in PKO mice. (D) Plot showing re-
combination efficiency in brain and peripheral tissues as revealed by Southern blot analysis (n¼2–4 mice; mean6 S.D.). (E) Representative quantitative western
blots showing MeCP2 expression in WT, PKO and null mice. WT whole brain reference samples were used to enable comparison of MeCP2 levels between different
gels and different tissues. Histone H3 was used as a loading control. (F) MeCP2 protein levels in PKO mice relative to WT levels across representative tissues
(mean6 S.D., n¼3). Abbreviations: W brain, whole brain; F brain, forebrain; M/H brain, Mid/hindbrain; Sk muscle, skeletal muscle; Cer, Cerebellum.
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system, whereas only a small minority of cells in peripheral tis-
sues express the protein.
Nestin-cre-mediated rescue of brain MeCP2 prevents the
onset of overt RTT-like phenotypes
KO mice survived to a median of 150 days, consistent with previ-
ous reports (33). In contrast, PKO and WT cohorts were fully via-
ble and fertile over the 52-week test period (Fig. 2A). Indeed, a
subgroup of PKO mice were maintained for 2 years with no
deaths recorded. Mice were assessed weekly for RTT-like signs us-
ing an established observational scoring system (33). Phenotype
severity increased over time in the KO mice (reflecting impaired
locomotion and breathing, tremor and poor general condition,
see Methods) and differed significantly from that of both WT and
PKO animals (P< 0.01) (Fig. 2B). WT and PKO mice did not show a
significant difference over the initial 30 week scoring period, but
when assessed again at one-year-old PKO mice showed a modest
reduction in activity and mild gait abnormalities compared to
WT (P< 0.05; Fig. 2B). Bodyweight was indistinguishable between
PKO and WT genotypes at 14–16 weeks, but at 1 year, PKO mice
weighed somewhat less than WT mice (Fig. 2C; mean body-
weight: WT¼ 38.561.0 g; PKO¼ 33.062.3 g; P< 0.05). These mi-
nor differences were not affected by the presence or absence of
the cre transgene in WT control mice, as a comparison of weights
and phenotypic scores between cre-positive and cre-negative
mice showed no significant differences (Supplementary Material,
Fig. S2).
In addition to gross severity and bodyweight, mice from
each genotype were examined for routine blood biochemistry
(Supplementary Material, Table S1) and histopathological
changes across a panel of tissues and organs (Supplementary
Material, Table S2). Blood serum measures showed modest
changes in a small number of markers in the KO group, but
there were no significant differences between PKO and WT sam-
ples across all measures. Histopathological evaluation revealed
no gross structural or histopathological changes for the major-
ity of tissues examined. Kidney sections from KO and PKO mice
revealed mild to moderate vacuolation, however, potentially in-
dicative of lipid accumulation.
PKOmice showmild hypoactivity but absence of
behavioural or gait defects
Having established that PKO mice did not differ markedly from
WT counterparts at a gross level, we next conducted a fine-
grained phenotypic analysis to detect archetypal RTT-like
features, including behavioural, locomotor and respiratory phe-
notypes. This analysis was conducted at 14–16 weeks of age, at
which time the surviving KO mice had become overtly symptom-
atic but could still complete most physiological and behavioural
testing paradigms. A previous study has shown that the nestin-
cre transgenic line used in this study displays a mild metabolic
and behavioural phenotype (37). To control for this potential con-
founding factor, all WT control mice used for the behavioural
analysis also contained the nestin-cre transgene. In order to as-
sess spontaneous movement, whose loss is prominent in all
Mecp2 knockout and knock-in models (11,17,38,39), mice were
monitored whilst ambulating freely in an open-field arena. KO
and PKO mice showed a reduction in both the distance moved
during the trial and in the amount of time spent rearing (regarded
as a measure of exploratory behaviour) compared to WT animals,
although the difference was more modest in PKO animals
(Fig. 3A and B, distance moved in 10 min: WT¼ 42426167;
PKO¼ 35236215; KO¼ 29636230 cm; rearing instances per ses-
sion; WT¼ 35.063.5; PKO¼ 22.462.9; KO¼ 15.062.2; P< 0.05).
We also assessed nest-building (40), as failure to utilise nesting
materials is associated with cognitive and motor impairments
(41–43). In agreement with previous studies of Mecp2-null mice
(44), KO mice showed a profound reduction in nest-building score
compared to WT (Fig. 3C; nesting score: KO¼ 0.9060.15;
PKO¼ 4.1060.25; WT¼ 4.0060.40; P< 0.001). In contrast, PKO
mice did not differ from WT (P> 0.05).
Hand stereotypies and gait abnormalities constitute major di-
agnostic criteria in RTT (1). Gait was therefore assessed using a
treadmill-based system. Previous studies using this approach (45)
have shown that KO mice develop a range of characteristic gait
Figure 2. Normal survival and absence of RTT-like signs in peripheral KO mice.
(A) Survival plot showing normal survival of WT (blue circles, n¼17) and PKO
mice (green squares, n¼7) compared to reduced lifespan in KO mice (red trian-
gles, n¼8). The median survival period was significantly reduced in KO mice
(***P<0.001, log-rank test). (B) Plot showing aggregate phenotype severity
(mean6SEM) based on an established observational scoring system. There was
a highly significant difference in score between WT and PKO animals from 8
weeks onwards when compared to KO (***P<0.001, Kruskal-Wallis test with
Dunn’s post hoc analysis). No significant difference was seen between WT and
PKO at the time of behavioural testing (15 weeks) but these groups differed sig-
nificantly at 1 year (*P<0.05). (C) Plot showing body weight changes over time
(mean6SEM). No significant differences were seen between genotypes at the
time of behavioural testing (15 weeks; P>0.05, one-way ANOVA) but PKO mice
had significantly lower bodyweight than WT mice when compared at 1 year
(***P<0.001, student’s unpaired t-test). In B) and C) group sizes at the start of the
experiment are as given in A).
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defects that increase in severity between 4 and 10 weeks of age.
We found that older symptomatic KO animals (14–16 weeks)
were largely incapable of continuous running (10 cm/s) on a
treadmill (Fig. 3D). PKO mice, on the other hand, displayed no dif-
ferences in stride frequency (Fig. 3E), stance width (Fig. 3F) or a
range of other gait parameters (Supplementary Material, Table
S2) compared to WT animals. These results indicate that absence
of MeCP2 from peripheral tissue leads to modest reductions in
overall locomotor activity without significantly affecting gait.
PKOmice show no difference in balance but marked
deficiency in exercise capacity
To further examine the motor function, balance and coordina-
tion were assessed using an inclined beam and rotarod. In the
beam test, KO mice showed deficits on both medium (time to
traverse 11 mm-wide beam: WT¼ 1.96 0.3; PKO¼ 2.560.4;
KO¼ 9.164.0 s; P< 0.05) and narrow beams (time to traverse 5
mm-wide beam: WT¼ 3.76 0.3 s; PKO¼ 4.66 0.8 s; KO¼
20.667.2 s; P< 0. 01) whereas PKO mice were not different from
WT (Fig. 4A and B). The rotarod test also revealed a markedly re-
duced performance in KO mice compared to both WT and PKO
littermates (Fig. 4C; latency to fall: WT¼ 243.5611.5;
PKO¼ 168614.9; KO¼ 91.5616.1 s; P< 0.001). In contrast to the
balance beam data, however, rotarod detected a reduction in
performance in the PKO mice compared to WT (P< 0.001). The
accelerating rotarod test is commonly used to assess balance
and coordination defects, but is also sensitive to endurance fa-
tigue. Since PKO mice did not display overt coordination and
balance defects in the beam test, we hypothesised that their
reduced rotarod performance was due to exercise fatigue asso-
ciated with the challenging nature of the accelerating rotarod
task. In order to test this hypothesis, mice were subjected to an
inclined treadmill task commonly used to test exercise fatigue
(46). A mild aversive stimulus ensures that mice carry out
the task to their true capacity and helps eliminate motivational
state as a confounding factor. KO mice showed a profoundly
impaired performance compared to both PKO and WT mice
(Fig. 4D; time sustained on treadmill; WT¼ 16.561.3; PKO¼
8.761.6; KO¼ 0.560.2 min; P< 0.001), but once again PKO mice
performed significantly less well than WT (P< 0.001). These re-
sults, in combination with the rotarod data, suggest that ab-
sence of MeCP2 from peripheral tissues leads to a marked
reduction in exercise capacity/increased vulnerability to fatigue,
which is not due to reduced motivation.
RTT-like respiratory phenotypes are absent in PKOmice
Abnormal breathing patterns, including breath holding and ap-
noea, are common features of RTT (47) and are also observed in
Mecp2 KO mice (34,48–51). They are typically attributed to dis-
ruption of autonomic or brainstem function, but as MeCP2 pro-
tein is expressed in lung, albeit at modest levels, and clinical
studies suggest that pulmonary lesions are common in RTT
(20), we looked for a peripheral contribution to respiratory
pathologies. We initially assessed conscious resting breathing
function using whole-body plethysmography. Respiratory
traces (Fig. 5A) were analysed for two prominent characteristics
of the RTT breathing phenotype: breath frequency/irregularity
and the presence of apnoeas. No differences were observed for
Figure 3. PKO mice show mild hypoactivity but absence of behavioural or gait defects. (A–B) Spontaneous motor and exploratory activity assessed using open-field.
Results show (A) total distance moved and (B) number of rearing events/session. There was a significant difference from WT in both PKO and KO mice. (C) Nesting be-
haviour was normal in PKO mice but impaired in KO mice. (D–F) Gait assessed using motorised treadmill. Results show (D) Proportion of mice capable of performing to
criterion (E) stride frequency and (F) stance width. All data other than (D) are mean6SEM. Numbers of animals per genotype are shown within each bar. Groups were
compared using one-way ANOVA with Tukey’s post hoc analysis. # indicates not determined due to mice being unable to perform to criterion. *P<0.05, **P< 0.01,
***P<0.001.
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breathing frequency between the three groups (Fig. 5B), but
analysis of the coefficient of variability (CV, %) of respiratory fre-
quency (Fig. 5C) revealed that KO animals showed a highly ir-
regular breathing pattern (mean CV¼ 0.6560.09%) compared to
both WT and PKO animals (P< 0.001). In contrast, PKO animals
displayed a highly regular breathing pattern (CV¼ 0.266 0.02%)
that was indistinguishable from WT (CV¼ 0.246 0.01%).
Similarly, WT and PKO mice showed negligible occurrence of
apnoeas (Fig. 5D; Apnoea number: WT¼ 0; PKO¼ 764.61/h;
P> 0.05) whilst KO mice showed a very high incidence of such
events (mean¼ 5016123.7/h) that differed from both WT and
PKO mice (P< 0.001). These results suggest that the absence of
MeCP2 from peripheral tissues does not lead to the respiratory
dysfunction typically present in Mecp2-null mice. Additionally,
histopathological examination of lung tissue biopsies (three per
genotype) revealed no gross structural abnormalities, inflam-
mation or other pathological signs in any of the genotypes
(Supplementary Material, Table S2).
Echocardiography results show absence of
cardiovascular phenotypes in PKOmice
Having assessed core phenotypes that define RTT, we next ex-
amined other peripheral tissue functions that are known to be
altered in RTT. Echocardiography revealed defects in heart rate
and cardiac contractile function in KO mice that were absent in
PKO and WT mice (Fig. 6Ai–iii). KO mice displayed a decreased
heart rate (Fig. 6B(i); WT¼512624; PKO¼ 471625; KO¼ 429616
bpm; P< 0.05), cardiac dilatation as evidenced by an increased
left ventricular (LV) end diastolic diameter (Fig. 6B(ii);
WT¼ 2.7660.08; PKO¼ 2.8060.08; KO¼ 3.306 0.18 mm; P< 0.05)
and a proportionally increased LV systolic diameter (Fig. 6B(iii);
WT¼ 1.306 0.06; PKO¼ 1.2860.08; KO¼ 1.6560.16 mm; P< 0.05).
LV free wall thickness (diastolic and systolic) and fractional
shortening (an index of contractility), however, did not differ be-
tween genotypes. Echocardiograph pulse-wave Doppler mea-
surements (Fig. 6C and D) revealed both a reduced E wave (early
diastolic LV filling) velocity (Fig. 6D(i); WT¼ 78.166.0;
PKO¼ 79.86 3.6; KO¼ 63.862.2 cm.s 1; P< 0.05;) and reduced A
wave (an index of LV filling via atrial contraction) velocity (Fig.
6D(ii); WT¼ 53.966.2; PKO¼ 59.56 3.4; KO¼ 44.86 3.1 cm.s 1;
P< 0.05) in KO mice compared to WT and PKO mice. The ratio of
E:A (an index of how well the LV fills; diastolic function) was not
different between groups (Fig. 6D(iii); WT¼ 1.5160.09;
PKO¼ 1.366 0.06; KO¼ 1.4560.07; P> 0.05). Overall, the data sug-
gest that PKO do not display the cardiac phenotypes seen KO
mice, suggesting that these defects arise in the CNS.
Normal skeletal muscle morphology and innervation in
PKOmice
Altered morphology of skeletal muscle including reduced fibre di-
ameter, was recently reported in Mecp2 KO mice (23). Histological
examination of the gastrocnemius muscle in the current study
Figure 4. PKO mice show no difference in balance but marked deficiency in exercise capacity. (A–B) Balance beam task showing time to traverse medium (A) and narrow
(B) beams. (C) Rotarod performance. (D) Exercise capacity measured using an elevated treadmill, with a steadily increasing speed. Results show time lasted on tread-
mill. Plots show mean6S.E.M. Number of animals per genotype are shown within each bar. Groups were compared using one-way ANOVA and Tukey’s post hoc analy-
sis. *P<0.05, **P< 0.01, ***P<0.001.
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showed a similar pattern of reduced fibre cross sectional area in
KO mice compared to WT and PKO (Fig. 7A and C;
WT¼ 1177664; PKO¼ 1045642; KO¼ 740653 mm2; P< 0.01) and
a mildly enhanced proportion of centrally nucleated fibres (Fig.
7A and D; WT¼ 0.6060.09; PKO¼ 0.9660.13; KO¼ 1.6460.29%;
P< 0.05), a putative marker of myofiber regeneration. No differ-
ences were observed between WT and PKO mice. Sections were
also stained for collagen but revealed no difference between ge-
notypes (Fig. 7B and E; WT¼ 2.5860.54; PKO¼ 2.4360.34;
KO¼ 3.8160.69%; P> 0.05), consistent with previous reports (23).
We also observed no difference in muscle capillary density be-
tween genotypes (Fig. 7G; WT¼ 54.264.8; PKO¼ 55.963.4;
KO¼ 46.665.4 capillaries per mm2; P> 0.05). Analysis of neuro-
muscular junctions revealed normal innervation of skeletal mus-
cle fibres by innervating axons from lower motor neurons in PKO
mice, with no evidence for denervation or abnormal junction
morphology observed (Supplementary Material, Fig. S3).
PKOmice show characteristic RTT-like bone phenotypes
Spinal deformity (scoliosis and kyphosis) and other skeletal
anomalies including early osteoporosis, osteopenia, bone frac-
tures and deformities are commonly observed in females with
RTT (3–5,52–54). In addition, studies in Mecp2 KO mice have
shown marked biochemical and biomechanical defects in bone
tissue (21,22). To test directly whether these bone defects are
central or peripheral in origin we conducted biomechanical test-
ing of long bone samples. Functional tests carried out on tibia
revealed a reduced ultimate load and stiffness in KO and PKO
mice compared to WT controls (Fig. 8A and B, ultimate load:
WT¼ 15.836 0.56; PKO¼ 13.9360.85; KO¼ 12.2260.67 N;
Stiffness: WT¼ 97.16 4.0; PKO 73.3164.1; KO¼ 72.966.4 N/mm;
P< 0.05). Further biomaterial testing revealed a similar pattern
in femur, with a reduced hardness of cortical bone in KO and
PKO mice compared to WT littermate controls (Fig. 8C;
WT¼ 64.763.4; PKO¼ 47.06 4.1; KO¼ 36.364.9 HV; P< 0.05).
Strikingly our results suggest a similarly reduced strength, hard-
ness and lower fracture threshold in both KO and PKO mice. In
the case of bone, absence of MeCP2 in peripheral tissues is likely
to be a primary cause of the observed defects.
Discussion
RTT is classically considered a neurological or neurodevelop-
mental disorder caused by lack of MeCP2 in the nervous system
(16,33,55). Recent interest in the possibility that some pheno-
types originate in the periphery is based on evidence that
MeCP2 is expressed in most tissues of the body, with high levels
reported in the post-mitotic cells of the heart and lungs (27–29).
Here we confirm that MeCP2 expression is widespread in mouse
tissues and establish that expression is much higher in the
brain that in any other tested tissue. Reports of comparably
high levels in lung and heart are not confirmed by our study. It
is likely that normalization of MeCP2 to cytoplasmic proteins,
whose abundance varies according to cell type, underlies this
discrepancy. We consider that normalization to histone H3,
whose abundance is constant regardless of cell origin, elimina-
tes this confounding variable.
The nervous system is the seat of most RTT-like
phenotypes
To investigate the potential role of MeCP2 in non-neuronal or-
gans, we developed a line of mice in which Mecp2 is expressed
Figure 5. RTT-like respiratory phenotypes are absent in PKO mice. (A) Representative whole-body plethysmograph traces showing regular and erratic breathing pat-
terns/apnoeas (arrows) in WT, stop-cre mice and in stop mice, respectively. (B) breathing frequency at rest, (C) breathing frequency variability and (D) apnoea fre-
quency. In (B–D), data are plotted as mean values6S.E.M. Numbers of animals per genotype are shown within each bar. Groups were compared using one-way ANOVA
and Tukey’s post hoc comparisons. ***P<0.001.
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Figure 6. Echocardiography parameters unchanged in PKO mice. (A) Example M-mode images from (i) WT, (ii) PKO and (iii) KO mice. The left ventricular internal diame-
ter is indicated in each image by the white dashed line. (B) Mean6SEM for M-mode measured parameters. (C) Example pulse-wave Doppler images from each of the ex-
perimental and control groups. Arrows indicate peak heights for both E (early diastolic filling) and A (atrial contribution to diastolic filling) waves. (D) Mean6SEM for
pulse-wave Doppler measured parameters. Numbers of animals per genotype are shown within each bar. Groups were compared using one-way ANOVA and Tukey’s
post hoc comparisons. *P<0.05.
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Figure 7. No significant muscle abnormalities in PKO mice. Representative images of gastrocnemius muscle cross section (A) stained with haematoxylin and eosin
(H&E) for measurement of myofiber cross sectional area; (B) stained with picrosirius red for measurement of collagen fibers; and (C) immunolabelled with an antibody
against the endothelial cell marker Griffonia simplicifolia lectin I (red) for measurement of capillary density. Black arrow indicates a centrally-located nucleus. Graphs
show (D) myofiber cross sectional area in mm2 (E) the proportion of fibers with a centrally-located nucleus (F) the proportion of the section composed of collagen fibers
and (G) the capillary density per mm2. Data are plotted as mean6SEM. Groups were compared using one-way ANOVA with Tukey’s post hoc comparisons. *P< 0.05,
**P< 0.01.
Figure 8. PKO mice show characteristic RTT-like bone phenotypes. Three-point bending test reveals reduced (A) ultimate load and (B) stiffness of tibia in PKO and KO
mice compared to WT. (C) Microindentation test in polished femur reveals significantly reduced cortical bone hardness in PKO and KO mice when compared with WT
controls. Plots show mean6S.E.M. Numbers of animals per genotype are shown within each bar. Groups were compared using one-way ANOVA with Tukey’s post hoc
comparisons. ***P<0.001, **P<0.01, *P<0.05.
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from embryonic day 8.5 within the nervous system, but is
largely absent from peripheral tissues. Our results reveal that
most key phenotypes observed in RTT mouse models can in-
deed be attributed to absence of MeCP2 in the nervous system.
The importance of nervous system dysfunction as the primary
origin of RTT-like phenotypes is exemplified by a lack of overt
RTT-like signs in PKO animals, as determined by observational
scoring (33,34,56–58), and absence of reduced survival typical of
KO male animals (16,17). These findings agree with previous
studies adopting a reciprocal strategy whereby selective dele-
tion of Mecp2 in the nervous system caused reduced survival
equivalent to that seen in global KO mice (16). Together, these
data show clearly that the severe/lethal effects of complete
MeCP2 deficiency can be attributed to lack of MeCP2 specifically
within the nervous system. Whilst there were no significant dif-
ferences in severity score or bodyweight between WT and PKO
over the initial 30 week trial period, equivalent to the maximal
survival period for the KO mice, there were detectable but mod-
est differences at 12 months. It is not clear whether these small
effects are attributable to MeCP2 deficiency in peripheral tissues
or if incomplete stop cassette deletion, leading to a small minor-
ity of MeCP2-deficient cells in the brain, is the underlying cause.
Detailed phenotyping further supports the view that the key
features of RTT, including breathing (49–51), balance and gait
disturbances (34,45,59) are not detected in PKO mice and there-
fore also reflect dysfunction within the nervous system. With
respect to breathing, a number of studies report disordered
GABAergic and serotonergic control of brain respiratory net-
works as the major cause of the disrupted breathing and ap-
noeas in RTT in patients and mouse models (60–63). One study,
however, reported that global KO of Mecp2 caused increased ap-
noeas in response to hypoxia induced hyperventilation (48),
whereas this effect was not seen in nervous system-specific
Mecp2-KO mice, suggesting a non-neuronal role for MeCP2 in re-
spiratory function. We did not specifically assess the response
of mice to hypoxia, but under baseline conditions, we observed
a complete rescue of apnoeas and episodic breathing in PKO
mice. Our results therefore confirm that these stereotypic RTT-
like features, at least under resting conditions, are due to ner-
vous system dysfunction.
Histopathological and blood serum biochemical screens also
showed few differences between genotypes confirming a lack of
widespread and overt tissue pathology as a result of MeCP2 defi-
ciency (16). The vast majority of organs showed no signs of
gross structural or pathological changes with the exception of
the kidney where there was some evidence of tubular vacuola-
tion in both PKO and KO mice, a feature often associated with
lipid accumulation and disordered lipid regulation (64,65).
Previous observations in Mecp2 KO mice (24) and in RTT patients
(25) have suggested that the absence of MeCP2 leads to altered
cholesterol biosynthesis and an increase in serum cholesterol
levels. More recently, mice in which Mecp2 was selectively de-
leted within the liver displayed fatty liver and an elevation in
serum cholesterol (26). This is in contrast to the current study
where no significant differences in serum cholesterol levels
were observed across the genotypes. It is possible that this dis-
crepancy results from background strain-specific differences, as
altered cholesterol metabolism was not reported in all Mecp2
knock-out lines (24). It is unlikely that our failure to detect dif-
ferences is affected by the reported altered regulation of genes
involved in lipid uptake and regulation in nestin-cre mice (37),
as this transgene is present in both PKO and control mice. It is
notable in this context that we did not observe the reported
weight differences between WT animals with or without the
nestin-cre transgene (Supplementary Material, Fig. S2), suggest-
ing that in our lines any effects are minimal.
A recent study in mice demonstrated structural alterations
in muscle fibre cross sectional area in Mecp2 KO mice, an effect
not seen in mice in which Mecp2 is selectively deleted in skeletal
muscle (23). The results of the current study support these find-
ings and suggest that the structural abnormalities in muscle fi-
bres seen in the KO mouse may be a consequence of disrupted
nervous system function such as aberrant skeletal muscle in-
nervation. However, we observed no difference in the structural
innervation of the neuromuscular junction or any evidence of
abnormal junction morphology in these mice. We also looked
for evidence of disorganisation and fibrosis in muscle tissue
sections from mice in the current study by staining for collagen,
but found no differences between genotypes.
Evidence for RTT-like phenotypes that arise outside the
nervous system
Although the nervous system is the primary source of defects in
the mouse model of RTT, our data suggest that peripheral
MeCP2 deficiency leads to phenotypes, including pronounced
exercise fatigue and defective bone properties. Several variables
implicit in the experimental design could potentially affect in-
terpretation of peripheral phenotypes. Firstly, it is important to
ensure that Mecp2 is activated in the vast majority of nervous
system cells by deletion of the stop cassette. Our observation
that levels of MeCP2 in PKO brain and spinal cord are closely
similar to WT (90%) support this, as does immunofluorescence
analysis of MeCP2 in specific CNS regions including the spinal
cord. Nevertheless, it could be argued that some moderate phe-
notypes are due to the deleterious effect of the small residual
population of MeCP2-negative nervous system cells. We note,
however, that phenotypes that require sophisticated brain func-
tion, including balance and innate nest building behaviour,
were indistinguishable between PKO and WT mice.
Furthermore, previous studies using a less efficient cre-based
strategy that resulted in 60–80% recombination in the nervous
system resulted in functional reversal of neuronal plasticity and
a range of motor phenotypes (33,34). This supports the interpre-
tation that defects seen in the PKO mice most likely originate in
MeCP2-deficient peripheral tissues. The finding that bone de-
fects are equally severe in the PKO mice, which have almost WT
levels in the brain, and in KO mice lacking almost all brain
MeCP2 strongly argues that this phenotype originates outside
the nervous system.
A second potential source of confounding effects would arise
if the absence of MeCP2 in nervous system prior to nestin-cre me-
diated activation of the gene has long-term phenotypic conse-
quences. This seems unlikely as nestin expression commences
early in development (day 8 of embryogenesis) and is pervasive
in neuronal progenitors, whereas MeCP2 expression is low at this
time, only increasing dramatically in the nervous system after
birth when most neurogenesis is complete (29). Accordingly, the
phenotypic effects of MeCP2 absence do not become apparent
until several weeks after birth. These observations suggest that
MeCP2 deficiency in early embryogenesis is probably phenotypi-
cally neutral. A third consideration affecting interpretation of the
results is the possibility that a small proportion of MeCP2-
positive cells in non-CNS tissues masks phenotypes that would
have been apparent if these tissues were truly null. The data
suggest less than 10% of normal levels of MeCP2 remains periph-
erally. This level of MeCP2 in the brain would cause a severe
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Rett-like phenotype, as even a 50% reduction gives detectable
Rett-like features (66,67). We found that recombination efficiency
in the kidney was higher and therefore more cells probably retain
MeCP2 expression. In addition, previous studies have shown nes-
tin expression in the vascular wall (68). Our ability to detect kid-
ney phenotypes or those impacted by vasculature function may
therefore be somewhat compromised.
A particularly robust finding in this study is the marked re-
duction in exercise capacity and vulnerability to fatigue displayed
by PKO animals. Whilst levels of spontaneous activity in the
open field test were only moderately reduced in comparison to
WT, when animals were challenged with more intensive tasks
(such as the elevated treadmill) the deficit was more pronounced,
with an almost 50% decrease in performance compared to WT.
Although less severe than the deficit in KO mice, the finding nev-
ertheless suggests an exercise fatigue phenotype that may be a
consequence of peripheral MeCP2 deficiency. Importantly, inertia
and reluctance to move are widely reported in Mecp2 KO mice
(33,69). So far we have been unable to attribute fatigue to a spe-
cific organ system. We consider cardiorespiratory dysfunction to
be an unlikely source as PKO mice did not differ from WT when
assessed for a range of cardiac (heart rate, diastolic filling param-
eters and left ventricular systolic and diastolic dilation) and respi-
ratory measures. Muscle morphology and neuromuscular
innervation were also normal in PKO mice. It is possible that fu-
ture studies assessing cardiac and respiratory responses under
exercise conditions, or assessing more subtle aspects of muscle
physiology and metabolism, may identify peripheral MeCP2-
mediated contributions to the observed fatigue phenotype.
An important unanticipated finding of our study is that func-
tional bone phenotypes seen in RTT-mice are due to a loss of
MeCP2 in peripheral tissue. A number of recent reports have
shown abnormalities in the biomechanical and structural proper-
ties of bone as well as biochemical differences and altered osteo-
blast activity in Mecp2 KO mice (21,22,70). It was unclear from
these studies, however, whether the primary cause was a local
deficiency of MeCP2 or a secondary consequence of MeCP2 defi-
ciency within the nervous system. Results from PKO animals in
the current study suggest that biomechanical and biomaterial de-
fects are in fact primarily peripheral in origin as KO and PKO ani-
mals both show similar levels of dysfunction when compared to
WT animals. This is an important finding as skeletal anomalies,
such as early osteoporosis and low energy fractures, are well doc-
umented in RTT patients (4,5,53,54,71). Treatments targeted solely
at the nervous system are unlikely to ameliorate these effects. It
is not clear from the current study whether the bone phenotypes
result from MeCP2 deficiency in bone cells per se, or whether they
are secondary to MeCP2-related defects in other peripheral tis-
sues. Recent evidence, however, has shown dysfunction in
MeCP2-deficient osteoblasts compared to wild-type cells suggest-
ing the phenotype may be primary in origin (70). The PKO mouse
model described here is likely to be an important tool in further
dissecting the physiology of these clinically relevant effects.
Materials and Methods
Animals
Cohorts of male PKO, WT, WT-Cre and KO mice were taken
from litters produced by mating hemizygous Nestin-Cre males
(35) (B6.Cg-Tg(Nes-cre)1Kln/J, Jackson Laboratories stock no.
003771) with heterozygous Mecp2þ/Stop females (33) (B6.129P2-
Mecp2tm2Bird/J, Jackson Laboratories stock no. 006849). Nestin-
Cre males were on an inbred C57BL6/J (C57) genetic background
and Mecp2þ/Stop females came from a breeding colony on a
mixed C57BL6/J, CBA/CaOlaHsd (C57/CBA) genetic background.
Initiated by crossing C57/CBA F1 WT males and Mecp2þ/Stop fe-
males, the colony had been maintained over many generations
by crossing Mecp2þ/Stop females from the colony with WT C57/
CBA F1 males, thus maintaining an approximately equal contri-
bution from each genetic background strain.
Experimental cohorts of Mecp2Stop/y (KO); Mecp2Stop/y, Nestin-
Cre (PKO); Mecp2þ/y (WT) and Mecp2þ/y, Nestin-Cre (WT-Cre) litter-
mates were genotyped by PCR as previously described (33).
All animals were housed with littermates and maintained
on a 12 h light/dark cycle and given access to food and water ad
libitum. Experiments were carried out in accordance with the
European Community Council Directive (86/609/EEC) and proj-
ect licences with local ethical approval under the UK Animals
(Scientific Procedures) Act (1986).
Southern blot
Genomic DNA was prepared from tissues and Southern blotted
as previously described (33). Briefly, Southern blots of EcoRI/NcoI
double-digested genomic DNA were probed with a 1.1 kb HindIII
fragment carrying the part of the mouse MeCP2 ORF contained
in exon 4. The percentage recombination of the Mecp2Stop allele
was quantified by scanning radiolabelled blots using a Typhoon
PhosphorImager (GE Healthcare) and determining the percent-
age of the total signal (StopþDeleted bands) contained in the
Stop band using ImageQuant software (GE Healthcare).
Western blot
Whole-cell homogenates of various tissues were prepared for
western blotting by homogenizing in NE1 buffer (20 mM HEPES
pH 7.9, 10 mM KCl, 1 mM MgCl2, 0.1% Triton X-100, 20% glycerol,
0.5 mM DTT, protease inhibitors cocktail (Roche)) using an
Ultra-Turrax T25 homogeniser, followed by incubation with
1000U/ml Benzonase (Sigma) for 15 min at room temperature.
An equal volume of 2 x SDS-PAGE sample buffer was added and
the samples were boiled, snap frozen and boiled again before
centrifuging for 5 min and taking the supernatant. Samples
were run on Bio-Rad TGX gradient gels (4–20%) and blotted onto
0.2lm nitrocellulose membrane by an overnight wet transfer in
25 mM Tris, 192 mM glycine at 25 V and 4 C. Membranes were
blocked in 5% skimmed milk powder in PBS before incubating at
4 C overnight with primary antibodies (anti-MeCP2 mouse
monoclonal, Sigma M7443, 1:1,000 and anti-histone H3 rabbit
polyclonal, Abcam ab1791, 1:10,000). Antibodies were diluted in
5% skimmed milk powder in PBSþ 0.1% TWEEN-20. After wash-
ing in PBS, membranes were incubated at RT for 2 h with IR-dye
secondary antibodies (IRDye 800CW donkey anti-mouse, IRDye
680LT donkey anti-rabbit, LI-COR Biosciences) diluted at
1:10,000 and then scanned using a LI-COR Odyssey machine.
Images were quantified using Image Studio Lite software (LI-
COR Biosciences). MeCP2 levels were normalised to histone H3
for each sample and values from each sample were expressed
as a percentage of the whole brain reference sample from the
same gel to enable comparison of MeCP2 levels between differ-
ent gels and different tissues.
Immunohistochemistry
Mice were humanely euthanized by intraperitoneal injection of
a lethal dose of Euthatal and transcardially perfused with 4%
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paraformaldehyde in 0.1 M phosphate buffer solution. Brain,
lung, heart and gastrocnemius muscles were dissected, post-
fixed, and dehydrated through increasing concentrations of eth-
anol and amyl acetate, before being embedded in paraplast.
Sections (5 mm) were collected on APES coated slides and dried
overnight at 37 C. Sections were then deparaffinised and rehy-
drated by Histo-Clear and decreasing concentrations of alcohol,
before being incubated in 0.1 M sodium citrate buffer (pH 6.0) for
2  5 min in a 950 watt microwave oven at full power for antigen
retrieval.
Anti-MeCP2
In order to block the endogenous peroxidase and prevent non-
specific binding, sections were first incubated in 3% hydrogen
peroxide (VWR) in methanol for 30 min, followed by a 1 h incu-
bation with 5% bovine serum albumin (Sigma) and 20% normal
goat serum (Sigma) in 0.05 M TBS at room temperature. The sec-
tions were then incubated with the primary antibody (mouse
anti-MeCP2, Sigma, 1: 250) overnight at 4 C, rinsed with 1% TBS/
Tween-20 and incubated with the secondary antibody (biotiny-
lated goat anti-mouse, Jackson, 1:200) for 1 h at room tempera-
ture. Sections were then treated with Avidin-Biotin-Complex
(Vectastain ABC kit, Elite-PK-6100 Vector Labs) for 30 min fol-
lowed by incubation with 3, 3-diaminobenzidine (DAB) (Vector
Laboratories). Finally, sections were stained with Mayer’s hema-
toxylin before being dehydrated and mounted with DPX. Images
were captured using a CCD camera (Axiocam HRc, Zeiss,
Germany) mounted on the light microscope (Eclipse 800, Nikon,
Japan).
Capillary density measurements
Sections were washed in 0.3 M PBST (3  10 min) and incubated
with 5% NGS in 0.3 M PBST for 1 h at room temperature. Sections
were then immunolabelled with rhodamine-labelled Griffonia
simplicifolia lectin-1(GSL-1; Vector Laboratories RL-1102; 1:100)
and incubated overnight at 4 C. Sections were rinsed with 0.3 M
PBST (3  10 min) and mounted with vectashield. Images were
collected using a BioRad MRC 1000 laser scanning confocal micro-
scope, 40X oil. The capillary density (number of capillaries per
mm2) was determined using ImageJ, with a minimum of five non
overlapping areas used for each sample.
Weight measurements and severity scoring
Each week all animals were weighed and scored using an obser-
vational severity scoring system, as previously described (33).
Briefly, animals were observed for each of six signs (tremor,
breathing, hind-limb clasping, gait, mobility, and overall general
condition) related to the Rett-like phenotype and given a score
of either 0 (absent i.e. as wild-type), 1 (present), or 2 (severe);
these scores are then added to give an overall aggregate severity
score out of 12 for each mouse. Scoring was carried out blind to
genotype. Animals were culled according to previously de-
scribed criteria (33) - scored 2 for tremor, breathing, or general
condition, or losing>20% of their bodyweight over a period of
1 week. Animals culled in this way were treated as having died
in the survival analysis.
Blood biochemistry
Mice were euthanized by CO2 inhalation and blood samples ac-
quired via terminal cardiac puncture. Samples were quickly
transferred to lithium heparin coated polypropylene tubes to
prevent clotting and transported within the hour to a special-
ised small animal clinical pathology lab for biochemical
analysis.
Histopathological analysis
An array of tissue samples were collected and embedded in par-
affin for sectioning and haematoxylin and eosin (H&E) staining.
Tissue sections were then assessed by a qualified veterinary pa-
thologist, blind to genotype.
Open field
Locomotor function and exploratory behaviours were investi-
gated using an open-field test. Mice were placed in the centre of
a 60 cm diameter circular arena and allowed to explore freely
for 10 min, during which time the arena was imaged using an
overhead digital camera and the animal was detected and
tracked using Ethovision 3.1 tracking software (Noldus Inc,
Leesburg, VA). A number of movement related parameters were
calculated. The test was carried out twice for each mouse on
consecutive days and the mean of these replicates was used as
the data point for each mouse for each parameter.
Nest building
Home cage nest quality was assessed using a previously de-
scribed scoring system (40). Briefly, mice were individually
caged overnight and supplied with 8 g of shredded biodegrad-
able paper strips as a nesting material, distributed evenly over
cage floor. Next morning nest quality was assessed using a five
point scoring system, which rated nests based on the formation
of a central nest hollow with surrounding walls (Fig. 2.1). The
lowest score of zero was given if the nesting material was
undisturbed, and no signs of interaction or manipulation were
seen. The maximum score of five was given when the mouse
had constructed a fully formed nest, with walls completely
enclosing a central hollow In order to assign a score, the lowest
point of the nest was identified and scored with an additional
0.25 being added to the score for each quarter of the nest that
had a higher wall. Scoring was carried out by two independent
scorers blind to genotype.
Gait analysis
Gait analysis was carried out using the DigiGait imaging system
(Mouse Specifics, Boston, MA) as previously described (26). Data
were collected at a running speed of 10 cm/s.
Balance beam
Mice were tested for a combination of balance and coordination us-
ing an inclined balance beam. Beams were either 5 mm or 11 mm
wide and the time taken to traverse a 50 cm span was recorded.
Six trials on each beam were carried out, three trials per day on
two consecutive days, and the mean of all six trials was used as
the data point for each animal. Animals that had not crossed the
beam within 1 min were given the maximum score of 60 s.
RotaRod
Motor learning and coordination were investigated using a 5-lane
accelerating rotarod (UGO Basile, Italy). The rotation speed was
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set to provide a gradual acceleration from 1rpm to 45 rpm over a
period of 5 min. Mice were scored for how long they remained on
the rod without falling or passively rotating. Three trials each
day, on two consecutive days, were carried out and the mean of
all 6 trials was used as the data point for each animal.
Exercise tolerance
Exercise capacity of the mice was investigated using an accelerat-
ing elevated treadmill. A mild aversive stimulus (electric shock)
was applied at the base of the treadmill in order to ensure the
mice performed to maximal physiological capacity. Mice were
placed on the treadmill at an initial speed of 10 cm/s and the
speed was increased by 2 cm/s every 2 min until maximum en-
durance was reached and the mice stopped running. At this point
the trial was terminated and the time was recorded (72).
Whole-body plethysmography
Respiratory phenotype was determined in conscious and unre-
strained mice using a whole body plethysmography apparatus
(EMMS, Bordon, U.K.). Mice were placed inside a Plexiglas cham-
ber and left for 20 min to become used to the environment after
which their breathing was monitored for 30 min. To account for
differing levels of movement and grooming between groups,
only data from periods in which the mice remained at quiet rest
was analysed. A continuous bias airflow supply allowed the ani-
mal to be kept in the chamber for extended periods of time.
Pressure changes caused by alterations in the temperature and
humidity of the air as it enters and leaves the subjects’ lungs
were detected by a pressure transducer, and a respiratory
waveform representing the breathing pattern of the animal
was produced. The waveform was then exported and analysed
using pClamp 10.2 (Molecular Devices Inc., California, USA).
Respiratory waveforms were analysed for breathing frequency,
frequency variability (using the coefficient of variability of the
waveforms) and the frequency of apnoeas (expiratory pauses
more than three respiratory cycles in length).
Echocardiography
Animals were anaesthetised by inhalation of 4% isofluorane gas
(Isoflo, Abbott Laboratories, USA) delivered in O2 at 1.5 l.min
 1
in an induction chamber until loss of righting reflex. The ani-
mals were then maintained on 1.5–2.0% isofluorane gas deliv-
ered in 1.0 l.min 1 O2 delivered by face mask. Fur was clipped
from the ventral thorax, cleaned with chlorhexidine spray and
warmed ultrasound gel applied to enhance acoustic transmis-
sion. B-mode and M-mode echocardiographic measurements of
the left ventricular chamber were taken with a 15 MHz neonatal
cardiac probe (Acuson Sequoia 512, Siemens U.K.) in the para-
sternal short-axis (transverse) view at the level of the papillary
muscles. Dimensions recorded were: left ventricular end dia-
stolic diameter (LVEDD), left ventricular end systolic diameter
(LVESD), end diastolic posterior wall thickness (PWD), end
systolic posterior wall thickness (PWS) and the change in LV di-
ameter from diastole to systole (fractional shortening; FS).
Blood velocity through the mitral valve was measured in the
apical four-chamber view using colour Doppler to identify the
atrio-ventricular blood flow and using pulse-wave Doppler to
measure velocity. Parameters recorded were; E wave (first com-
ponent of LV filling due to relaxation of the LV chamber),
A wave (second component of LV filling due to atrial contrac-
tion) and E:A ratio (an indicator of LV diastolic function).
Structural analysis of muscle
Gastrocnemius muscles were dissected and immediately fixed
in 4% paraformaldehyde in 0.1 M phosphate buffer solution for
24 h, before being processed and paraffin embedded. Cross-
sections (7mm) were then stained, either with Haematoxylin and
Eosin to measure myofiber cross-sectional area, or with
Picrosirius red to measure intramuscular connective tissue.
Bright field images were then captured from non-overlapping
fields of the entire section and analysed using ImageJ (NIH,
USA). The myofiber cross-sectional area was measured by man-
ually tracing the circumference of each fibre following a previ-
ously described protocol (73). To quantify connective tissue
levels, images were converted to an RGB stack and the green
channel was selected as it produces higher contrast. Red-
stained collagen was identified by applying thresholding of
grayscale to measure the percentage of collagen in relation to
the total field area.
Neuromuscular junction analysis
Mice were culled by inhalation of isoflurane. The lower limb
lumbrical and interscutularis muscles were dissected out and
fixed in 4% paraformaldehyde for 30 min. Neuromuscular junc-
tions were then immunolabelled for the pre-synaptic proteins
SV2 (synaptic vesicle) and 2H3 (neurofilament), and post-
synaptic AChRs as previously described (74,75). For each indi-
vidual muscle (lower limb lumbrical and interscutularis), counts
were performed on 40 neuromuscular junctions. Representative
images were acquired on a Zeiss LSM 710 confocal microscope.
Bone biomechanical tests
Biomechanical testing of tibia and micro-hardness testing of
polished femur section was conducted as described previously
(21). Briefly, mouse tibial shafts were scanned by micro-
computed tomography (SKYSCANVR 1172/A lCT Scanner, Bruker,
Belgium) before being subjected to a three-point bending test
for stiffness and strength of cortical bone using a Zwick/Roell
z2.0 testing machine (Leominster, UK) with a 100 N load cell.
Tibias were placed between supports with 8 mm separation and
load applied at the mid-point between the supports at a rate of
0.1 mm.s 1 until fracture occurred. Data were analysed to de-
termine values of stiffness, ultimate load and Young’s modulus
(21). The material properties of the bone were assessed using a
micro-indentation hardness test performed on segments of
polished femur located in the distal mid-shaft region. Micro-
hardness testing was performed using a Wolpert Wilson Micro-
Vickers 401MVA machine (UK), with an applied load of 25 g for
100 s. Each sample was tested at seven points and the Vickers
hardness number (HV) calculated (21).
Statistical Analysis
Group data are expressed as mean6SEM throughout the text.
Groups were compared using Kruskal-Wallis tests with Dunn’s
post hoc analysis (for survival and composite severity score), un-
paired t-test (bodyweight) and one-way ANOVA with Tukey’s post
hoc analysis (all other tests). Analysis was carried out using
Minitab 17.0 (Minitab, USA). Significance was accepted at P< 0.05.
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